Author Identifier

Wei Wang

https://orcid.org/0000-0002-1430-1360

Document Type

Journal Article

Publisher

Impact Journals LLC

Place of Publication

United States

School

School of Medical and Health Sciences

RAS ID

24962

Funders

National Health and Medical Research Council

National Natural Science Foundation of China (NSFC 81372586, 81370083, 81273170)

Beijing Nova Program (Z141107001814058)

Joint Project of the Australian National Health and Medical Research Council and the National Natural Science Foundation of China (NHMRC APP1112767-NSFC 81561128020)

Australian National Health and Medical Research Council Grant

Grant Number

NHMRC Numbers : 1046711, 1112767

Comments

Wang, H., Luo, C., Zhu, S., Fang, H., Gao, Q., Ge, S., ... & Wang, W. (2017). Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts. Oncotarget, 8(35), 59376-59386.

https://doi.org/10.18632/oncotarget.19587

Abstract

Colorectal cancer (CRC) is one of the most common malignant neoplasms worldwide. Except for the existing fecal occult blood test, colonoscopy and sigmoidoscopy, no widely accepted in vitro diagnostic methods have been available. To identify potential peptide biomarkers for CRC, serum samples from a discovery cohort (100 CRC patients and 100 healthy controls) and an independent validation cohort (91 CRC patients and 91 healthy controls) were collected. Peptides were fractionated by weak cation exchange magnetic beads (MB-WCX) and analysed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDITOF MS). Five peptides (peaks at m/z 1895.3, 2020.9, 2080.7, 2656.8 and 3238.5) were identified as candidate biomarkers for CRC. A diagnostic panel based on the five peptides can discriminate CRC patients from healthy controls, with an accuracy of 91.8 %, sensitivity of 95.6 %, and specificity of 87.9 % in the validation cohort. Peptide peaks at m/z 1895.3, 2020.9 and 3238.5 were identified as the partial sequences of complement component 4 (C4), complement component 3 (C3) and fibrinogen a chain (FGA), respectively. This study potentiated peptidomic analysis as a promising in vitro diagnostic tool for diagnosis of CRC. The identified peptides suggest the involvement of the C3, C4 and FGA in CRC pathogenesis.

DOI

10.18632/oncotarget.19587

Creative Commons License

Creative Commons Attribution 3.0 License
This work is licensed under a Creative Commons Attribution 3.0 License.

Included in

Oncology Commons

Share

 
COinS